Johnson & Johnson Announces European Commission Approval of Agreement to Supply 200 Million Doses of Janssen’s COVID-19 Vaccine Candidate18 Jan, 2021
Johnson & Johnson (NYSE: JNJ) (the Company) today announced the European Commission (EC), acting on behalf of the European Union (EU) Member States, has approved an Advance Purchase Agreement in which the Janssen Pharmaceutical Companies will supply 200 million doses of its COVID-19 vaccine candidate to EU Member States following approval or authorization from regulators. The EU Member States also have the option to secure up to 200 million additional doses.
“The COVID-19 pande...
The coronavirus disease 2019 (COVID-19) pandemic has caused significant disruptions to education for surgical residents across the country. Residents have experienced reduced operative exposure, decreased time caring for hospitalized patients, and altered rotation schedules. A number of studies have been published since the start of the COVID-19 pandemic regarding the effect of the crisis on residents and resident education across fields including internal medicine, emergency medicine, o...
More than 150 coronavirus vaccines are in development across the world—and hopes are high to bring one to market in record time to ease the global crisis. Several efforts are underway to help make that possible, including the U.S. government’s Operation Warp Speed initiative, which has pledged $10 billion and aims to develop and deliver 300 million doses of a safe, effective coronavirus vaccine by January 2021. The World Health Organization is also coordinating global efforts to...
The Lancet confirms that preprint paper will stay in their future strategy.
For full reading download the document.
In countries that have achieved a low incidence of COVID-19 infection, such as Australia and New Zealand, disease elimination has been proposed. Yet we do not have a definition of elimination for COVID-19. Both these countries implemented early, widespread, and strict disease mitigation strategies. With low cumulative incidence, most of the population in these countries remain susceptible to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Before the availability of a vaccin...
Coronavirus (COVID-19) Update: FDA Issues Emergency Use Authorization to Yale School of Public Health for SalivaDirect, Which Uses a New Method of Saliva Sample Processing18 Aug, 2020
Today, the U.S. Food and Drug Administration issued an emergency use authorization (EUA) to Yale School of Public Health for its SalivaDirect COVID-19 diagnostic test, which uses a new method of processing saliva samples when testing for COVID-19 infection.
“The SalivaDirect test for rapid detection of SARS-CoV-2 is yet another testing innovation game changer that will reduce the demand for scarce testing resources,” said Assistant Secretary for Health and COVID-19 Testing Coo...
A potential coronavirus vaccine developed by Oxford University with pharmaceutical giant AstraZeneca has produced a promising immune response in a large, early-stage human trial, according to newly released data published Monday in the medical journal The Lancet.
The researchers are calling their experimental vaccine ChAdOx1 nCoV-19 (AZD1222). It combines genetic material from the coronavirus with a modified adenovirus that is known to cause infections in chimpanzees...
Continuing chemotherapy and immunotherapy treatment in cancer patients with Covid-19 is not a risk to their survival, a study suggests.
It also recommends further research into the drug hydroxychloroquine, which appeared to benefit some patients.
The findings, from 890 infected cancer patients in the UK, Spain, Italy and Germany, could help identify who is most at risk from coronavirus.
Breast cancer patients had half the death rate of other patients.
More than 140 teams of researchers are racing to develop a safe and effective coronavirus vaccine.
Researchers around the world are racing to develop a vaccine against Covid-19, with more than 140 candidate vaccines now tracked by the World Health Organization (WHO).
Vaccines normally require years of testing and additional time to produce at scale, but scientists are hoping to develop a coronavirus vaccine within 12 to 18 months.
Vaccines mimic the...
The preliminary results of a clinical trial suggest a new treatment for Covid-19 reduces the number of patients needing intensive care, according to the UK company that developed it.
The treatment from Southampton-based biotech Synairgen uses a protein called interferon beta which the body produces when it gets a viral infection.
The protein is inhaled directly into the lungs of patients with coronavirus, using a nebuliser, in the hope that it will stimulate an immune respon...
An study of the RECOVERY Group bring good news about the use of Dexamethasone in COVID-19 patients.
Coronavirus disease 2019 (Covid-19) is associated with diffuse lung damage. Glucocorticoids may modulate inflammation-mediated lung injury and thereby reduce progression to respiratory failure and death.
In this controlled, open-label trial comparing a range of possible treatments in patients who were hospitalized with Covid-19, we ra...
A $2bn procurement fund aimed at ensuring that poorer countries can access doses of a potential coronavirus vaccine has been announced at a virtual summit hosted by the UK.
The announcement was made at the third Gavi vaccine alliance replenishment summit, a virtual pledging event that separately raised $8.8bn, above the target of $7.4bn, for the private-public alliance’s general work on immunising millions of people worldwide from longstanding diseases such as measles.